BHWM
GMAB icon

Beaird Harris Wealth Management’s Genmab GMAB Stock Holding History

Beaird Harris Wealth Management’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$78 Hold
3
– – ﹤0.01% 685
2026
Q1 		$76 Hold
3
– – ﹤0.01% 663
2025
Q4 		$87 Hold
3
– – ﹤0.01% 683
2025
Q3 		$87 Buy
+3
New +$73 ﹤0.01% 707

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Beaird Harris Wealth Management's GMAB Position: Q2 2026 in Review

Beaird Harris Wealth Management held its Genmab (GMAB) position steady in Q2 2026 at 3 shares worth $78. The position accounts for ﹤0.01% of the portfolio, ranked #685.

Beaird Harris Wealth Management first reported a position in GMAB in Q3 2025 and has held it in 4 quarters since. The position peaked at $87 in Q4 2025. 290 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Beaird Harris Wealth Management held 3 shares of Genmab worth $78 as of Q2 2026.
  • Beaird Harris Wealth Management left its Genmab share count unchanged in Q2 2026.
  • Genmab made up ﹤0.01% of Beaird Harris Wealth Management's portfolio in Q2 2026, its #685 holding.
  • Beaird Harris Wealth Management first reported a position in Genmab in Q3 2025 and has held it in 4 quarters since.
  • Beaird Harris Wealth Management's Genmab position peaked at $87 in Q4 2025.
  • 290 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Beaird Harris Wealth Management's 13F filing for Q2 2026, filed 8 Jul 2026.